Here are four details to note.
1. Baxter paid $153 million upfront, but future contingent payments could be required.
2. Recothrom is the only topical hemostat from recombinant DNA to be approved in the U.S. and Canada.
3. Preveleak is a surgical sealant used in vascular reconstruction. It is approved for use in Europe and the U.S.
4. Baxter’s Advanced Surgery Division President Wil Boren said the acquisition offers additional options for addressing intraoperative bleeding.
“Our top priority right now is working with customers and distributors to ensure a smooth transition,” Mr. Boren said.
More articles on supply chain:
BioElectronics to study pain management, recovery after knee replacement — 4 notes
Medline plans $19.6M investment for Iowa expansion — 6 insights
Envision Healthcare completes $2.1B American Medical Response divesture — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.